Abstract Case Report
IntroductIon
Chryseobacterium indologenes is an uncommon human pathogen that has been rarely reported in the literature as a cause of infection because of its low virulence. Chryseobacterium indologenes has a potential to causes severe nosocomial infections, especially in immunocompromised, critically ill patients and has a multidrug resistant pattern. Infections due to Chryseobacterium spp. occurs more commonly in the elderly (>65 years old)patients with nosocomial pneumonia and bacteraemia being more common, sometimes associated with prolonge indwelling devices. In the hospital environment, this bacteria has ability to contaminate and persist in fluid-containing apparatuses.The infections caused by Chryseobacterium indologenes are on rise because of selection pressure and prolong ICU stay. We report two cases of hospital acquired Chryseobacterium sepsis with fatal outcome.
Case 1
A 61-year-old male who was a diagnosed case of carcinoma breast Stage 4 postoperative, postchemotherapy, and postradiotherapy with interstitial fibrosis on palliative chemotherapy was admitted in an emergency with fever, pain abdomen and respiratory distress from the past 5 days.
The patient was intubated, resuscitated and transferred to the intensive care unit (ICU) in a shock state. All the relevant cultures were sent and broad-spectrum antibiotics started. His initial investigation showed leukopenia with serum procalcitonin (PCT) of 136 with a pneumonic patch on the chest X-ray. Ultrasonography abdomen showed normal study. All the cultures came negative but the shock did not improve, so empirically polymyxin B was added on the 5 th day looking at our local microbiological sensitivity pattern. Cultures were resent and endotracheal (ET) tube aspirate showed growth Stenotrophomonas maltophilia sensitive to cotrimoxazole. Hence, cotrimoxazole was started and the other antibiotics decelerated. Percutaneous tracheostomy was done as it was difficult to wean the patient. The patient slightly improved with PCT of 34 but again developed fever and worsening of shock. All the relevant cultures were resent, and antifungal was added. The patient developed acute kidney
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Case 2
A 68-year-old female who was a known case of multiple connective tissue disorder with interstitial lung disease and hypertension came to the hospital with fever and respiratory distress. The patient was managed in the ward with antibiotics and noninvasive ventilation. On the 3 rd day, the patient developed labored breathing and desaturation, so she was intubated and transferred to ICU. All the relevant cultures were sent, and antibiotics were stepped-up. ET aspirate grew Pseudomonas and was managed with meropenem and polymyxin, for which the bacteria were sensitive. Still, there was no improvement and antifungal was started, and ET aspirate cultures were resent which showed growth of C. indologenes which was pandrug resistant [ Table 1 ]. Cotrimoxazole was started as bacteria showed MIC of 80. The patient developed AKI which was managed with dialysis. Repeat ET aspirate after 10 days also showed the same organism with the same pandrug-resistant pattern. The patient did not improve and expired after 20 days of hospital stay.
Cultures from the water sources from the ICU were sent to find the source, but the C. indologenes was not traceable.
C. indologenes, formally known as Flavobacterium indologenes,
is a Gram-negative, oxidase-positive, nonglucose-fermenting bacillus. [1] It is usually found in plants, soil, food materials, and fresh and marine water sources. [2] They are normally not present in the human microflora, but they exist on water systems and wet surfaces which are even resistant to chlorination. In a hospital, they can get colonized to medical devices such as humidifiers, respirators, ET tubes, and tracheostomy tubes and serve as potential reservoirs of infection. In immunocompromised patients or in patients on prolonged broad-spectrum antibiotics, the contamination of surgically implanted devices such as intravenous catheters and prosthetic valves is also reported. [3] Bacteremia and pneumonia are the most commonly reported infections caused by C. indologenes. [4, 5] C. indologenes possesses chromosomal metallo-beta-lactamases, so it is naturally resistant to aminoglycosides. It typically exhibits resistance to multiple antibiotics with newer fluroquinolones, trimethoprim-sulfamethoxazole, and rifampin shows some sensitivity. [6] There is an increasing trend of C. indologenes infections after rise in colistin and tigecycline usage. [7] There are no established recommendations for the management of C. indologenes infections. Therefore, choosing an appropriate antibiotic therapy for this pathogen is very difficult.
Our case is unique due to the pandrug-resistant pattern of C. indologenes and the associated mortality. Our patients were elderly and were in the immunosuppressed state on the broad spectrum of antibiotics with invasive lines in situ and prolong ICU stay. Above findings also comply with the studies from Taiwan which showed increasing prevalence of C. indologenes infections in the recent past with increasing resistance pattern. These studies also showed that C. indologenes infections were associated with high mortality as in our cases, especially in bacteremic patients. [7, 8] Our findings suggest that this pathogen should be included among the causes of ICU-acquired bacteremia, especially in patients with a prolonged stay in an ICU, and specific recommendations for its management should be established.
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Trimethoprim/ sulfamethoxazole 80 R ≧320 R
MIC: Minimum inhibitory concentration, R: Resistant
